Protocol of a prospective multicenter study on comorbidity impact on multiple sclerosis and antibody-mediated diseases of the central nervous system (COMMIT)
Comorbidities in patients with multiple sclerosis (MS) and antibody-mediated diseases of the central nervous system (CNS) including neuromyelitis optica spectrum disorder (NMOSD), and myelin oligodendrocyte glycoprotein (MOG)-antibody-associated disease (MOGAD) are common and may influence the cours...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Frontiers Media
2024
|
| _version_ | 1811140203194089472 |
|---|---|
| author | Samadzadeh, S Adnan, R Berglova, P Barzegar, M Debrabant, B Roikjaer, SG Levy, M Petzold, A Palace, J Flanagan, EP Mariotto, S Skou, ST Froelich, A Lotan, I Messina, S Geraldes, R Asseyer, S Stiebel-Kalish, H Oertel, FC Shaygannejad, V Sahraian, MA Kim, HJ Bennett, JL Böttcher, C |
| author_facet | Samadzadeh, S Adnan, R Berglova, P Barzegar, M Debrabant, B Roikjaer, SG Levy, M Petzold, A Palace, J Flanagan, EP Mariotto, S Skou, ST Froelich, A Lotan, I Messina, S Geraldes, R Asseyer, S Stiebel-Kalish, H Oertel, FC Shaygannejad, V Sahraian, MA Kim, HJ Bennett, JL Böttcher, C |
| author_sort | Samadzadeh, S |
| collection | OXFORD |
| description | Comorbidities in patients with multiple sclerosis (MS) and antibody-mediated diseases of the central nervous system (CNS) including neuromyelitis optica spectrum disorder (NMOSD), and myelin oligodendrocyte glycoprotein (MOG)-antibody-associated disease (MOGAD) are common and may influence the course of their neurological disease. Comorbidity may contribute to neuronal injury and therefore limit recovery from attacks, accelerate disease progression, and increase disability. This study aims to explore the impact of comorbidity, particularly vascular comorbidity, and related risk factors on clinical and paraclinical parameters of MS, NMOSD and MOGAD. We propose COMMIT, a prospective multicenter study with longitudinal follow-up of patients with MS, NMOSD, and MOGAD, with or without comorbidities, as well as healthy subjects as controls. Subjects will be stratified by age, sex and ethnicity. In consecutive samples we will analyze levels of inflammation and neurodegeneration markers in both fluid and cellular compartments of the peripheral blood and cerebrospinal fluid (CSF) using multiple state-of-the-art technologies, including untargeted proteomics and targeted ultrasensitive ELISA assays and quantitative reverse transcription polymerase chain reaction (RT-qPCR) as well as high-dimensional single-cell technologies i.e., mass cytometry and single-cell RNA sequencing. Algorithm-based data analyses will be used to unravel the relationship between these markers, optical coherence tomography (OCT) and magnetic resonance imaging (MRI), and clinical outcomes including frequency and severity of relapses, long-term disability, and quality of life. The goal is to evaluate the impact of comorbidities on MS, NMOSD, and MOGAD which may lead to development of treatment approaches to improve outcomes of inflammatory demyelinating diseases of the CNS. |
| first_indexed | 2024-09-25T04:18:15Z |
| format | Journal article |
| id | oxford-uuid:0394b439-5e18-41e2-9ae0-dca3017c1365 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-09-25T04:18:15Z |
| publishDate | 2024 |
| publisher | Frontiers Media |
| record_format | dspace |
| spelling | oxford-uuid:0394b439-5e18-41e2-9ae0-dca3017c13652024-07-27T19:33:48ZProtocol of a prospective multicenter study on comorbidity impact on multiple sclerosis and antibody-mediated diseases of the central nervous system (COMMIT)Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:0394b439-5e18-41e2-9ae0-dca3017c1365EnglishJisc Publications RouterFrontiers Media2024Samadzadeh, SAdnan, RBerglova, PBarzegar, MDebrabant, BRoikjaer, SGLevy, MPetzold, APalace, JFlanagan, EPMariotto, SSkou, STFroelich, ALotan, IMessina, SGeraldes, RAsseyer, SStiebel-Kalish, HOertel, FCShaygannejad, VSahraian, MAKim, HJBennett, JLBöttcher, CComorbidities in patients with multiple sclerosis (MS) and antibody-mediated diseases of the central nervous system (CNS) including neuromyelitis optica spectrum disorder (NMOSD), and myelin oligodendrocyte glycoprotein (MOG)-antibody-associated disease (MOGAD) are common and may influence the course of their neurological disease. Comorbidity may contribute to neuronal injury and therefore limit recovery from attacks, accelerate disease progression, and increase disability. This study aims to explore the impact of comorbidity, particularly vascular comorbidity, and related risk factors on clinical and paraclinical parameters of MS, NMOSD and MOGAD. We propose COMMIT, a prospective multicenter study with longitudinal follow-up of patients with MS, NMOSD, and MOGAD, with or without comorbidities, as well as healthy subjects as controls. Subjects will be stratified by age, sex and ethnicity. In consecutive samples we will analyze levels of inflammation and neurodegeneration markers in both fluid and cellular compartments of the peripheral blood and cerebrospinal fluid (CSF) using multiple state-of-the-art technologies, including untargeted proteomics and targeted ultrasensitive ELISA assays and quantitative reverse transcription polymerase chain reaction (RT-qPCR) as well as high-dimensional single-cell technologies i.e., mass cytometry and single-cell RNA sequencing. Algorithm-based data analyses will be used to unravel the relationship between these markers, optical coherence tomography (OCT) and magnetic resonance imaging (MRI), and clinical outcomes including frequency and severity of relapses, long-term disability, and quality of life. The goal is to evaluate the impact of comorbidities on MS, NMOSD, and MOGAD which may lead to development of treatment approaches to improve outcomes of inflammatory demyelinating diseases of the CNS. |
| spellingShingle | Samadzadeh, S Adnan, R Berglova, P Barzegar, M Debrabant, B Roikjaer, SG Levy, M Petzold, A Palace, J Flanagan, EP Mariotto, S Skou, ST Froelich, A Lotan, I Messina, S Geraldes, R Asseyer, S Stiebel-Kalish, H Oertel, FC Shaygannejad, V Sahraian, MA Kim, HJ Bennett, JL Böttcher, C Protocol of a prospective multicenter study on comorbidity impact on multiple sclerosis and antibody-mediated diseases of the central nervous system (COMMIT) |
| title | Protocol of a prospective multicenter study on comorbidity impact on multiple sclerosis and antibody-mediated diseases of the central nervous system (COMMIT) |
| title_full | Protocol of a prospective multicenter study on comorbidity impact on multiple sclerosis and antibody-mediated diseases of the central nervous system (COMMIT) |
| title_fullStr | Protocol of a prospective multicenter study on comorbidity impact on multiple sclerosis and antibody-mediated diseases of the central nervous system (COMMIT) |
| title_full_unstemmed | Protocol of a prospective multicenter study on comorbidity impact on multiple sclerosis and antibody-mediated diseases of the central nervous system (COMMIT) |
| title_short | Protocol of a prospective multicenter study on comorbidity impact on multiple sclerosis and antibody-mediated diseases of the central nervous system (COMMIT) |
| title_sort | protocol of a prospective multicenter study on comorbidity impact on multiple sclerosis and antibody mediated diseases of the central nervous system commit |
| work_keys_str_mv | AT samadzadehs protocolofaprospectivemulticenterstudyoncomorbidityimpactonmultiplesclerosisandantibodymediateddiseasesofthecentralnervoussystemcommit AT adnanr protocolofaprospectivemulticenterstudyoncomorbidityimpactonmultiplesclerosisandantibodymediateddiseasesofthecentralnervoussystemcommit AT berglovap protocolofaprospectivemulticenterstudyoncomorbidityimpactonmultiplesclerosisandantibodymediateddiseasesofthecentralnervoussystemcommit AT barzegarm protocolofaprospectivemulticenterstudyoncomorbidityimpactonmultiplesclerosisandantibodymediateddiseasesofthecentralnervoussystemcommit AT debrabantb protocolofaprospectivemulticenterstudyoncomorbidityimpactonmultiplesclerosisandantibodymediateddiseasesofthecentralnervoussystemcommit AT roikjaersg protocolofaprospectivemulticenterstudyoncomorbidityimpactonmultiplesclerosisandantibodymediateddiseasesofthecentralnervoussystemcommit AT levym protocolofaprospectivemulticenterstudyoncomorbidityimpactonmultiplesclerosisandantibodymediateddiseasesofthecentralnervoussystemcommit AT petzolda protocolofaprospectivemulticenterstudyoncomorbidityimpactonmultiplesclerosisandantibodymediateddiseasesofthecentralnervoussystemcommit AT palacej protocolofaprospectivemulticenterstudyoncomorbidityimpactonmultiplesclerosisandantibodymediateddiseasesofthecentralnervoussystemcommit AT flanaganep protocolofaprospectivemulticenterstudyoncomorbidityimpactonmultiplesclerosisandantibodymediateddiseasesofthecentralnervoussystemcommit AT mariottos protocolofaprospectivemulticenterstudyoncomorbidityimpactonmultiplesclerosisandantibodymediateddiseasesofthecentralnervoussystemcommit AT skoust protocolofaprospectivemulticenterstudyoncomorbidityimpactonmultiplesclerosisandantibodymediateddiseasesofthecentralnervoussystemcommit AT froelicha protocolofaprospectivemulticenterstudyoncomorbidityimpactonmultiplesclerosisandantibodymediateddiseasesofthecentralnervoussystemcommit AT lotani protocolofaprospectivemulticenterstudyoncomorbidityimpactonmultiplesclerosisandantibodymediateddiseasesofthecentralnervoussystemcommit AT messinas protocolofaprospectivemulticenterstudyoncomorbidityimpactonmultiplesclerosisandantibodymediateddiseasesofthecentralnervoussystemcommit AT geraldesr protocolofaprospectivemulticenterstudyoncomorbidityimpactonmultiplesclerosisandantibodymediateddiseasesofthecentralnervoussystemcommit AT asseyers protocolofaprospectivemulticenterstudyoncomorbidityimpactonmultiplesclerosisandantibodymediateddiseasesofthecentralnervoussystemcommit AT stiebelkalishh protocolofaprospectivemulticenterstudyoncomorbidityimpactonmultiplesclerosisandantibodymediateddiseasesofthecentralnervoussystemcommit AT oertelfc protocolofaprospectivemulticenterstudyoncomorbidityimpactonmultiplesclerosisandantibodymediateddiseasesofthecentralnervoussystemcommit AT shaygannejadv protocolofaprospectivemulticenterstudyoncomorbidityimpactonmultiplesclerosisandantibodymediateddiseasesofthecentralnervoussystemcommit AT sahraianma protocolofaprospectivemulticenterstudyoncomorbidityimpactonmultiplesclerosisandantibodymediateddiseasesofthecentralnervoussystemcommit AT kimhj protocolofaprospectivemulticenterstudyoncomorbidityimpactonmultiplesclerosisandantibodymediateddiseasesofthecentralnervoussystemcommit AT bennettjl protocolofaprospectivemulticenterstudyoncomorbidityimpactonmultiplesclerosisandantibodymediateddiseasesofthecentralnervoussystemcommit AT bottcherc protocolofaprospectivemulticenterstudyoncomorbidityimpactonmultiplesclerosisandantibodymediateddiseasesofthecentralnervoussystemcommit |